Dynavax Technologies | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
AbbVie USD 10.71B 458M 2024-12
Adma Biologics USD 63.33M 3.67M 2024-12
Amgen USD 5.97B 781M 2024-12
AstraZeneca USD 12.17B 1.06B 2024-12
Biogen USD 1.87B 44.1M 2024-12
BioMarin Pharmaceutical USD 611.17M 53.89M 2024-12
Bristol-Myers Squibb USD 9.13B 94M 2024-12
Dynavax Technologies USD 58.62M 8.92M 2024-12
Gilead Sciences USD 5.99B 17M 2024-12
Glaxosmithkline GBP 5.6B 94M 2024-12
Merck USD 11.92B 852M 2024-12
Neurocrine Biosciences USD 618.4M 4.3M 2024-12
Novartis USD 10.23B 294M 2024-12
Pfizer USD 12.11B 718M 2024-12
Regeneron Pharmaceuticals USD 3.22B 1.88B 2024-12
Roche Holding CHF 11.69B 48M 2024-12
Sarepta Therapeutics USD 526.11M 150.63M 2024-12
TG Therapeutics USD 92.79M 18.25M 2024-12
Vertex Pharmaceuticals USD 2.49B 109.3M 2024-12



Dynavax Technologies Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.